(19)
(11) EP 3 478 716 A2

(12)

(88) Date of publication A3:
01.03.2018

(43) Date of publication:
08.05.2019 Bulletin 2019/19

(21) Application number: 17746544.0

(22) Date of filing: 30.06.2017
(51) International Patent Classification (IPC): 
C07K 16/18(2006.01)
A61K 39/00(2006.01)
(86) International application number:
PCT/IB2017/053991
(87) International publication number:
WO 2018/007924 (11.01.2018 Gazette 2018/02)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
MA MD

(30) Priority: 02.07.2016 US 201615201429

(71) Applicants:
  • Prothena Biosciences Limited
    Co. Dublin A96 T927 (IE)
  • University Health Network
    Toronto, Ontario M5G 2C4 (CA)

(72) Inventors:
  • NIJJAR, Tarlochan S.
    Orinda, CA 94563 (US)
  • CHAKRABARTTY, Avijit
    Vaughn, Ontario L4K 2E1 (CA)
  • HIGAKI, Jeffrey N
    San Mateo, CA 94402 (US)

(74) Representative: FRKelly 
27 Clyde Road
Dublin D04 F838
Dublin D04 F838 (IE)

   


(54) ANTI-TRANSTHYRETIN ANTIBODIES